Sarepta Therapeutics Inc (SRPT.OQ)
24 May 2019
Sarepta Therapeutics Inc beefed up its gene therapies portfolio through the purchase of its partner Myonexus Therapeutics Inc and reported positive data for a genetic disorder therapy from the privately held company, sending its shares up 9 percent on Wednesday.
Feb 27 Sarepta Therapeutics Inc said on Wednesday it would buy privately held gene therapy company Myonexus Therapeutics Inc for $165 million, moving deeper into an emerging and lucrative field within the biotech sector.
Feb 27 Sarepta Therapeutics Inc said on Wednesday it exercised its option to buy privately held gene therapy maker Myonexus Therapeutics Inc for $165 million.